4 citations
,
July 2024 in “Pharmacology Research & Perspectives” This phase 2a, double-blind study evaluated the effects of ritlecitinib on brainstem auditory evoked potentials (BAEP) and intraepidermal nerve fiber (IENF) histology in 71 adults with alopecia areata. Participants received either ritlecitinib or a placebo for 9 months. The study found no significant differences in BAEP changes or IENF histology between the ritlecitinib and placebo groups. Additionally, there was no increased incidence of neurological or audiological adverse events associated with ritlecitinib. These findings suggest that the axonal swelling and BAEP changes observed in dogs are not clinically relevant in humans.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
4 citations
,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
6 citations
,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
227 citations
,
April 2023 in “The Lancet” 
148 citations
,
March 2022 in “The New England Journal of Medicine” Baricitinib was effective in treating alopecia areata in two major trials.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
67 citations
,
March 2021 in “Dermatology and Therapy” Alopecia areata greatly harms quality of life, causing emotional and social issues.
138 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.
30 citations
,
September 2020 in “Journal of Patient-Reported Outcomes” Alopecia Areata (AA) causes significant emotional distress, including feelings of embarrassment, depression, and anxiety, and impacts social interactions and daily activities.
134 citations
,
July 2020 in “Experimental dermatology” Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.
88 citations
,
August 2019 in “Frontiers in immunology” Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.
95 citations
,
November 2018 in “Australasian journal of dermatology” Alopecia areata treatment varies, with no optimal method established yet.
53 citations
,
July 2018 in “Drug design, development and therapy” Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
162 citations
,
October 2014 in “Autoimmunity reviews” Alopecia areata is caused by the immune system attacking hair follicles.
52 citations
,
September 2014 in “Nature medicine” JAK inhibitors might help treat alopecia areata.
53 citations
,
September 2013 in “Journal of Investigative Dermatology” Hair follicle cells help protect against immune attacks by regulating T-cell activity.
2 citations
,
February 2009 in “Journal of Evidence-Based Medicine” No treatment showed significant long-term hair growth benefits for alopecia areata.
164 citations
,
April 2008 in “Cochrane library” Current treatments for alopecia show no significant long-term benefits.
